Genmab (GMAB) said that a Phase 3 study of epcoritamab combined with lenalidomide met its primary objective, helping adults with relapsed or refractory diffuse large B-cell lymphoma stay progression-free longer than those receiving standard therapy.
The regimen cut the risk of disease progression or death by 60% under US censoring rules and 56% under censoring rules used outside the US, with both results statistically significant, Genmab said Monday in a statement.
Genmab said the safety profile was consistent with what's known for each drug. The company and its partner, AbbVie (ABBV), plan to discuss the findings with global regulators.
The ongoing Phase 3 trial is enrolling adults who received at least one prior systemic therapy and were not eligible for stem-cell transplant or CAR-T treatment.
Genmab shares rose 2.2% in after-hours trading, and AbbVie eased 0.2%.